FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2537938090> ?p ?o ?g. }

• W2537938090 abstract "Introduction: Many pediatric clinical trials fail due to use of sub-therapeutic dosing. This phase I / II clinical trial was designed to evaluate the short-term safety, pharmacokinetics (PK), and preliminary efficacy of udenafil, a phosphodiesterase type 5 inhibitor, in adolescents following Fontan palliation to inform dose selection for a phase III clinical trial.Methods: This was a dose escalation trial with 5 dosing cohorts of 6 subjects each at 37.5 mg, 87.5 mg, and 125 mg daily, as well as 37.5 mg and 87.5 mg twice daily (bid) for 5 days. Efficacy testing (echocardiography, exercise stress test, endothelial function assessment) was performed at baseline and on day 5. A control cohort of 6 subjects underwent exercise testing without drug administration. Serum samples for PK analysis were collected on days 6-8. Adverse events (AE) were recorded throughout the 8-day study period and for 3 months thereafter. Comparison between baseline and day 5 testing was performed using ANOVA and visual trend lines. PK analysis was performed using a non-linear mixed effects model.Results: The trial enrolled 36 subjects at a mean age of 15.8 years (58.3% male). Subject characteristics were similar between cohorts. No drug-related serious AEs were reported during the study period, while 24 subjects had non-serious AEs possibly or probably related to study drug. Headache was the most common, occurring in 20 of the 30 subjects. Other possibly or probably medication related side effects occurring in more than one subject included: facial flushing (10 subjects), nasal congestion (7), spontaneous penile erection (6), nausea (3), and abdominal discomfort (2). The 87.5 mg bid cohort achieved the highest steady state serum concentration (172 ng/mL, range 117-202), the highest maximal concentration (506 +/- 188 ng/mL), and the greatest area under the curve for 24 hours (6701 +/- 1591 ng*hr/mL). Efficacy test results did not change significantly in any cohort.Conclusion: Udenafil was safe and well tolerated at all dosing levels while the 87.5 mg bid cohort achieved the highest serum drug level. With a 5-day treatment period and small sample size no significant clinical changes were observed. These data suggest that the 87.5 mg bid regimen may be most appropriate for a Phase III clinical trial." @default.
• W2537938090 created "2016-10-28" @default.
• W2537938090 creator A5001375991 @default.
• W2537938090 creator A5001434802 @default.
• W2537938090 creator A5002040990 @default.
• W2537938090 creator A5004545282 @default.
• W2537938090 creator A5023054843 @default.
• W2537938090 creator A5032437498 @default.
• W2537938090 creator A5034227091 @default.
• W2537938090 creator A5034449055 @default.
• W2537938090 creator A5047491313 @default.
• W2537938090 creator A5047562035 @default.
• W2537938090 creator A5055410117 @default.
• W2537938090 creator A5059699120 @default.
• W2537938090 creator A5071239027 @default.
• W2537938090 creator A5085757749 @default.
• W2537938090 date "2015-11-10" @default.
• W2537938090 modified "2023-09-26" @default.
• W2537938090 title "Abstract 14024: Results of a Phase I / II Multicenter Investigation of Udenafil in Adolescents After Fontan Palliation" @default.
• W2537938090 hasPublicationYear "2015" @default.
• W2537938090 type Work @default.
• W2537938090 sameAs 2537938090 @default.
• W2537938090 citedByCount "0" @default.
• W2537938090 crossrefType "journal-article" @default.
• W2537938090 hasAuthorship W2537938090A5001375991 @default.
• W2537938090 hasAuthorship W2537938090A5001434802 @default.
• W2537938090 hasAuthorship W2537938090A5002040990 @default.
• W2537938090 hasAuthorship W2537938090A5004545282 @default.
• W2537938090 hasAuthorship W2537938090A5023054843 @default.
• W2537938090 hasAuthorship W2537938090A5032437498 @default.
• W2537938090 hasAuthorship W2537938090A5034227091 @default.
• W2537938090 hasAuthorship W2537938090A5034449055 @default.
• W2537938090 hasAuthorship W2537938090A5047491313 @default.
• W2537938090 hasAuthorship W2537938090A5047562035 @default.
• W2537938090 hasAuthorship W2537938090A5055410117 @default.
• W2537938090 hasAuthorship W2537938090A5059699120 @default.
• W2537938090 hasAuthorship W2537938090A5071239027 @default.
• W2537938090 hasAuthorship W2537938090A5085757749 @default.
• W2537938090 hasConcept C112705442 @default.
• W2537938090 hasConcept C126322002 @default.
• W2537938090 hasConcept C197934379 @default.
• W2537938090 hasConcept C2777288759 @default.
• W2537938090 hasConcept C535046627 @default.
• W2537938090 hasConcept C71924100 @default.
• W2537938090 hasConcept C72563966 @default.
• W2537938090 hasConceptScore W2537938090C112705442 @default.
• W2537938090 hasConceptScore W2537938090C126322002 @default.
• W2537938090 hasConceptScore W2537938090C197934379 @default.
• W2537938090 hasConceptScore W2537938090C2777288759 @default.
• W2537938090 hasConceptScore W2537938090C535046627 @default.
• W2537938090 hasConceptScore W2537938090C71924100 @default.
• W2537938090 hasConceptScore W2537938090C72563966 @default.
• W2537938090 hasLocation W25379380901 @default.
• W2537938090 hasOpenAccess W2537938090 @default.
• W2537938090 hasPrimaryLocation W25379380901 @default.
• W2537938090 hasRelatedWork W1986000961 @default.
• W2537938090 hasRelatedWork W2002729775 @default.
• W2537938090 hasRelatedWork W2047149042 @default.
• W2537938090 hasRelatedWork W2066441931 @default.
• W2537938090 hasRelatedWork W2170034991 @default.
• W2537938090 hasRelatedWork W2363981502 @default.
• W2537938090 hasRelatedWork W2385249866 @default.
• W2537938090 hasRelatedWork W2385569832 @default.
• W2537938090 hasRelatedWork W2386384198 @default.
• W2537938090 hasRelatedWork W2390326425 @default.
• W2537938090 hasRelatedWork W2407358499 @default.
• W2537938090 hasRelatedWork W2471246678 @default.
• W2537938090 hasRelatedWork W2512823213 @default.
• W2537938090 hasRelatedWork W2600201609 @default.
• W2537938090 hasRelatedWork W2759583910 @default.
• W2537938090 hasRelatedWork W2770649524 @default.
• W2537938090 hasRelatedWork W2774440400 @default.
• W2537938090 hasRelatedWork W2921347657 @default.
• W2537938090 hasRelatedWork W3184991811 @default.
• W2537938090 hasRelatedWork W3205613756 @default.
• W2537938090 hasVolume "132" @default.
• W2537938090 isParatext "false" @default.
• W2537938090 isRetracted "false" @default.
• W2537938090 magId "2537938090" @default.
• W2537938090 workType "article" @default.